Skip to main content
Signal8

Tessera Defense & Homeland Security Inc. (HLSQ)

Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.

Sector: Services-Prepackaged Software

Industry: Biotechnology

Tessera Defense and Homeland Security Inc logo

Tessera Defense and Homeland Security Inc

OTC:HLSQHealthcare
AH+0.00%$0.0244
Close$0.0244+8.93%
Mkt Cap$634K
EV-
Float10.01M
O/S26M
VOL297K sh
$ Vol$7K
RVOL0.22×
Inst Own0.6%
SI0.9%
Net Cash/Sh-
Dilution
Tessera Defense and Homeland Security Inc logoOTC:HLSQAH$0.0244+0.00%

Tessera Defense & Homeland Security Inc. (HLSQ) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 49 SEC filings.

Shelf registration
S-3 filed Feb 9, 2026, effective Feb 13, 2026
Source: 424B3 filed Feb 13, 2026
At-the-market (ATM) program
Yes, sales agreement dated Dec 7, 2023
Source: 8-K filed Oct 13, 2026
Warrants outstanding
12 warrant series recorded as outstanding
Most recent offering
ATM sale, closed Jun 30, 2026
Source: 10-Q filed Aug 19, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro